ArticleBMC cardiovascular disorders2026
Incremental prognostic value of AI-based coronary CT angiography combined with PET/CT dynamic myocardial perfusion imaging in patients with suspected or confirmed coronary artery disease.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCoronary computed tomography angiography (CCTA) and positron emission tomography/computed tomography (PET/CT) myocardial perfusion imaging (MPI) provide complementary anatomical and functional information for coronary artery disease (CAD). However, the prognostic value of integrating CCTA-derived coronary imaging characteristics with PET-MPI parameters remains to be established. Therefore, this retrospective single-center study aimed to evaluate the prognostic and incremental value of integrating artificial intelligence (AI)-based CCTA with PET/CT MPI for predicting major adverse cardiovascular events (MACEs) in patients with CAD.
methodsPatients with suspected or confirmed CAD underwent PET/CT dynamic MPI and contemporaneous CCTA were retrospectively enrolled and followed for at least 12 months for MACEs. MACEs were defined as the occurrence of at least one of the following endpoints: all-cause death, nonfatal myocardial infarction, new-onset heart failure, rehospitalization for angina, or late coronary revascularization. Clinical characteristics, AI-derived CCTA features, and PET-MPI parameters were collected. To reduce the number of candidate variables and mitigate potential multicollinearity, LASSO regression was applied as an exploratory variable selection method. Variables with non-zero coefficients were subsequently included in multivariable Cox proportional hazards models to assess their associations with the risk of MACEs. Dose-response relationships were further explored using restricted cubic spline analyses. Incremental prognostic value was evaluated using hierarchical Cox regression models.
resultsA total of 71 patients (mean age 60.17 ± 12.36 years; 59.2% male) were included, with 18 MACEs occurring over a median follow-up of 25.69 months. Patients with MACEs more frequently exhibited obstructive coronary stenosis, abnormal PET-MPI semiquantitative parameters, reduced CT-derived fractional flow reserve (CT-FFR), and a higher burden of high-risk plaque features (all P < 0.05). The total number of high-risk plaque features was significantly associated with the risk of MACEs (HR 1.898, 95% CI 1.015-3.546; P = 0.045) and showed a trend toward a linear relationship with event risk. PET-MPI semiquantitative parameters improved prognostic performance beyond the clinical baseline model (P = 0.011), and further incorporation of high-risk plaque feature count significantly improved model performance across functional models (all P < 0.05).
conclusionsAI-driven CCTA integrated with PET/CT dynamic MPI may provide prognostic information in patients with CAD. PET-MPI semiquantitative parameters and the total number of high-risk plaque features were associated with risk and may offer complementary and incremental value for predicting MACEs. These findings warrant further validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.